In Re: Diet Drugs V.

451 F. App'x 165
Court of Appeals for the Third Circuit·Decided November 14, 2011·No. 11-1617·Unpublished

Opinion

OPINION OF THE COURT

JORDAN, Circuit Judge.

Richard Farr appeals the February 2, 2011 order of the United States District Court for the Eastern District of Pennsyl *167 vania denying his supplemental claim for Matrix compensation benefits under the Diet Drugs Nationwide Class Action Settlement Agreement (the “Settlement Agreement” or “Agreement”). For the reasons that follow, we will affirm.

I. Background

A. The Diet Drugs Class Action Settlement

This appeal arises out of a claim from the settlement of multi-district products liability litigation regarding the diet drugs Pondimin and Redux, previously sold by American Home Products (“AHP”). 1 See In re Diet Drugs Prods. Liab. Litig., 543 F.3d 179, 181 (3d Cir.2008). In November 1999, Wyeth, the successor in interest to AHP, joined plaintiffs’ representatives in a Settlement Agreement, which was approved by the District Court in August 2000. See id. at 181. Under the terms of the Agreement, Wyeth was required to contribute funds for the payment of claims. See id. at 180. The AHP Settlement Trust (the “Trust”), acting through its trustees and claims administrator, administers and reviews claims to determine the benefits, if any, that a class member is qualified to receive under the terms of the Settlement Agreement. See id.

B. Matrix Compensation Under the Settlement Agreement

Claimants who qualify for benefits receive compensation based on one of four payment matrices: A-l, A-2, B-l, and B-2 (each, a “Matrix”). 2 Each Matrix describes the amount which a claimant is entitled to recover based on the level of severity of the medical condition and the age at which the claimant was first diagnosed as suffering from that level of severity. There are five levels within each Matrix, and the severity of the condition determines a claimant’s level within a Matrix. A claimant is eligible for compensation under A-l unless the claimant has one or more reduction factors as provided in the Settlement Agreement. If a reduction factor exists, benefits are determined by Matrix B-l, which is also referred to as the reduced payment matrix. Two such reduction factors are mitral valve prolapse and chordae tendineae rupture.

To receive Matrix benefits, a claimant must submit a Matrix compensation benefits claim form (a “Green Form”) to the Trust. A physician must complete a portion of a Green Form on behalf of the claimant, answering questions concerning the claimant’s medical condition and providing the appropriate documentation that may be relevant to determine the amount of compensation payable. Based on both the information in a Green Form and the supporting documentation, the Trust makes a Matrix benefits determination, subject to the audit provisions of the Settlement Agreement. 3 If the Trust identi- *168 fíes an inconsistency in the information provided in the Green Form, the Trust reviews the submitted documentation to resolve the inconsistency.

Claimants who received Matrix benefits at one level may make a supplemental claim if their condition worsens to a point which would qualify them for a higher level of compensation. Specifically, § IV. C.3 of the Settlement Agreement provides that a claimant “can step up to higher Matrix-Level Conditions and will be paid the incremental dollar amount, if any, by which the Matrix payment for the higher Matrix-Level Condition exceeds the Matrix payment previously received.” (App. at 355 (emphasis added).)

C. Fan-’s Claims With the Trust

1. September 2000 Claim

Farr filed a Green Form in September 2000 seeking A-l Level IV benefits (the “September 2000 Claim”), after undergoing mitral valve surgery. 4 Two questions that a Green Form asks, among others, is whether a claimant has “[mjitral valve prolapse” or “[c]hordae tendinae rupture.” 5 (App. at 85.) Based on Farr’s physician’s review of Farr’s medical reports, Farr’s physician marked “no” for both of those questions. However, the medical records attached to the September 2000 Green Form indicated that Farr in fact had “mi-tral valve prolapse” (App. at 293) and “chordae tendineae [that are] fused and slightly thickened,” (App. at 150).

As a result of that discrepancy, Wyeth submitted the September 2000 Green Form to the Trust for audit as to whether Farr’s physician made a material misrepresentation when he indicated Farr did not have chordae tendineae rupture. In the initial audit report, the auditing cardiologist wrote that the echocardiogram attached to the September 2000 Green Form “clearly show[ed] ruptured chordae.” (App. at 106.) Despite that finding, the auditing cardiologist checked the box which indicated that the physician’s answers on the September 2000 Green Form and the medical information reviewed were consistent and reflected a reasonable medical judgment 6 and that Farr qualified for A-l Severity Level IV benefits. Eleven days later, though, the same auditing cardiologist issued a revised report indicating that the physician’s answers on the September 2000 Green Form and the medical information received did not reflect a reasonable medical judgment and that Farr only qualified for B-l Severity Level III benefits.

Nevertheless, the Trust did not pay B-l Severity Level III benefits to Farr for the September 2000 Claim. A debate arose instead. On July 23, 2001, the Trust’s claims administrator, C. Judson Hamlin, wrote a letter to the trustees of the Trust and counsel for Wyeth indicating that the Trust had not dealt fairly with Farr’s claim. Specifically, Hamlin expressed concern that a Trust representative might have asked the cardiologist to revisit the original audit report, and that the revised *169 audit report arrived at a different conclusion than it had in the original audit report based on the same evidence. 7 Hamlin concluded that, if the Trust did not award Farr A1 Level IV benefits, it must reveal to Farr the “two contradictory audit reports so he may properly pursue his remedy in the courts.” (App. at 117.) In response, on August 2, 2009, counsel for Wyeth maintained that Wyeth believed Farr was only entitled to B-l Level III benefits, noting that it would “certainly present Mr. Farr’s entire file to the Court for an objective assessment of whether the Claim should be paid on the A or B Matrix.” (App. at 111.)

In the end, on August 9, 2001, the Trust issued a final determination letter (the “2001 Final Determination Letter”) that appears to reflect a compromise. 8

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Diet Drugs V., 451 F. App'x 165 (3d Cir. 2011).

451 F. App'x 165 (In Re: Diet Drugs V.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related